Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBS6
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**GBS6** is Pfizer's investigational hexavalent maternal vaccine for prevention of invasive disease caused by *Streptococcus agalactiae* in newborns and young infants. Also designated **PF-06760805**, it comprises capsular polysaccharide antigens from six Group B Streptococcus serotypes conjugated to the carrier protein CRM197. Maternal intramuscular vaccination is intended to generate serotype-specific maternal antibodies that are transferred transplacentally to the infant, providing passive protection during early life. GBS6 received FDA Fast Track designation in 2017 and Breakthrough Therapy designation in 2022; Pfizer's Phase 3 BEATRIX study is evaluating the vaccine in healthy pregnant participants and their infants. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-breakthrough-therapy-designation-pfizers-group-b))
- Other names
- Group B Streptococcus 6-Valent Polysaccharide Conjugate VaccineHexavalent Group B Streptococcus Capsular Polysaccharide Conjugate Vaccine
02
Targets
GBS CPS (Group B Streptococcus capsular polysaccharide)GBS CPS III (Group B Streptococcus capsular polysaccharide type III)GBS CPS Ia (Group B Streptococcus capsular polysaccharide type Ia)GBS CPS Ib (Group B Streptococcus capsular polysaccharide Ib)
Beyond the preview
Go deeper on GBS6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBS6.